Johnson & Johnson News

New Brunswick, NJ (Nov. 3, 2009) – Johnson & Johnson today announced global restructuring initiatives designed to strengthen the company’s position as the world’s leading global health care company.  The company is taking steps to prioritize its innovation efforts around the many growth opportunities in health care and to execute aggressively on bringing key new products to market. .....

Cork, Ireland (October 31, 2009) –Tibotec announced today results of a new study (VX950-C208), which showed that sustained virologic response (SVR) was achieved in more than 80 percent of treatment-naïve patients with chronic genotype 1 hepatitis C virus (HCV) who took telaprevir, administered either every 8 hours or every 12 hours,  in combination with standard of care.  Telaprevir, an investigat

Cincinnati, OH (October 26, 2009)– Ethicon Endo-Surgery today announced results from two newly published studies that demonstrate a minimally invasive approach in three common procedures resulted in a reduced rate of complications and lower overall cost of care, including a difference of more than $15,000 on average for minimally invasive colectomies, when compared to open surgery.

Bridgewater, NJ. (October 23, 2009) – Cordis Corporation announced today a nationwide voluntary recall of all lots of the CROSSOVER™ Sheath Introducer due to complaints about stretching or fracture of the sheath during use. .....

New Brunswick, NJ, (October 22, 2009) -- Anne M. Mulcahy, Chairman of Xerox Corporation (NYSE: XRX), today was appointed to the Board of Directors of  Johnson & Johnson (NYSE: JNJ), the world's most broadly based health care products company.....

Raritan, NJ (October 20, 2009) – More than one million Americans – most of them women –suffer from a painful and little-known bladder condition called interstitial cystitis (IC). To raise awareness and recognize the ongoing struggles of people living with this painful bladder condition, Ortho Women’s Health & Urology™ announces the second annual , October 19-23, 2009. .....

Philadelphia, PA – October 19, 2009 – Phase 3 data reported for the first time show that once every four week subcutaneous injections of SIMPONI™ (golimumab) resulted in significantly greater inhibition of structural damage compared with placebo plus methotrexate in patients with active rheumatoid arthritis (RA) and active psoriatic arthritis (PsA).

Toronto (October 19, 2009) - Tibotec, a division of Janssen-Ortho Inc. ("Tibotec"), in collaboration with Health Canada, would like to inform patients of important safety information regarding severe skin reactions in patients receiving HIV combination therapy including INTELENCE (etravirine) tablets.

Philadelphia, PA (October 19, 2009) – New long-term data from two pivotal, Phase 3 clinical trials showed that patients with active rheumatoid arthritis (RA) receiving SIMPONI™ (golimumab) every four weeks achieved sustained improvements in signs and symptoms and physical function response through one year.

Skillman, NJ (October 19, 2009) – Women who participated in a stress management program prior to or during their second IVF cycle had a 160 percent greater pregnancy rate than women who did not participate in a program, according to a study presented today at the American Society for Reproductive Medicine’s 65 Annual Meeting.....